Erik Kinnman is a physician, Ph.D., with specialist training in neurology and pain management, a Doctor of Medicine and an associate professor at Karolinska Institutet, and holds an Executive MBA from the Stockholm School of Economics. Erik has 25 years of experience from senior positions within Life Science and is currently a Board member of Stayble Therapeutics and Immune System Regulation and the CEO of Sprint Bioscience. He has previously been the CEO of Abliva AB (formerly Neurovive) and has held senior positions at AstraZeneca and Sobi, among others, and worked as a financial analyst at Danske Bank. Erik does not own any shares or share-related instruments in Vivesto.

Peter Zonabend, Chairman of the Board of Vivesto, says: ”Erik has a robust industry experience and high academic competence. Erik has also, for many years held senior positions in listed Life Science companies, which has given him the expertise to lead Vivesto. The Board is therefore very pleased that Erik is joining us, and we look forward to the future with confidence.”

For further information:

Peter Zonabend, Chairman of the Board of Vivesto

Phone: +46 18-50 54 40

E-mail: IR@vivesto.com

About Vivesto AB
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit www.vivesto.com.